TATI, also known as pancreatic secretory trypsin inhibitor (PSTI) or serine peptidase inhibitor Kazal 1 type (SPINK1), is a trypsin inhibitor that functions mainly in the pancreas, where it serves as a suppressor of premature trypsinogen activation.
Variable | S-TATI− | % | S-TATI+ | % | p-Value | Missing/% (n = 90) |
---|---|---|---|---|---|---|
Number of patients | 69 | 76.7 | 21 | 23.3 | ||
Age | 60.8 | 65.1 | 0.054 | |||
Gender | ||||||
Male | 52 | 78.8 | 14 | 21.2 | ||
Female | 17 | 70.8 | 7 | 29.2 | 0.4 | |
Smoking | ||||||
Never | 27 | 96.4 | 1 | 3.6 | ||
Posterior wall of oropharynx | ||||||
1 | ||||||
20.0 | ||||||
4 | ||||||
80.0 | ||||||
<0.001 ** | ||||||
HPV | ||||||
HPV− | 21 | 56.8 | 16 | 43.2 | ||
HPV+ | 48 | 90.6 | 5 | 9.4 | <0.001 ** |
Variable | OS | DSS | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
TATI in | Tumor 0–1 |
% | TATI in Tumor 2–3 |
% | p-Value | Missing/% (n = 77) |
HR | 95% CI | p-Value | HR | 95% CI | p-Value |
Age | 1.08 | 1.03–1.13 | 0.004 * | 1.07 | 1.01–1.14 | |||||||
Number of patients | 20 | 26.0 | 0.018 * | |||||||||
35 | ||||||||||||
76.1 | ||||||||||||
0.6 | ||||||||||||
Variable | TATI in Lymphocytes 0–1 | % | TATI in Lymphocytes 2–3 | % | p-Value | Missing/% (n = 76) |
||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
57 | 63.3 | |||||||||||||
Number of patients | 30 | |||||||||||||
Smoking | ||||||||||||||
39.5 | 46 | Age | 0.034 * | 64.4 | 0.205 | |||||||||
61.1 | 0.2 | Ex-smoker versus never | 1.20 | 0.27–5.40 | 0.816 | 0.62 | ||||||||
60.5 | ||||||||||||||
Age | 62.6 | 61.3 | 0.6 | Gender | Gender 0.10–3.98 | 0.615 | ||||||||
Current smoker versus never | 4.14 | 1.22–14.06 | ||||||||||||
Male | 15 | 25.4 | 0.023 * | 2.43 | 0.64–9.18 | 0.192 | ||||||||
Male | 44 | 23 | 39.7 | 3574.6 | 60.3 | Stage III–IVversusStage I–II | 1.71 | 0.70–4.20 | 0.243 | 2.19 | 0.72–6.64 | 0.168 | ||
HPV-versus HPV+ | 1.01 | 0.36–2.83 | 0.988 | 0.96 | 0.27–3.43 | 0.955 | ||||||||
S-TATI | 2.47 | 1.26–4.84 | 0.009 * | 2.54 | 1.07–6.02 | 0.034 * |
Variable | |||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Female | 5 | 27.8 | 13 | 72.2 | 0.8 | ||||||||||
Female | 7 | 38.9 | 11 | 61.1 | 0.9 | Smoking | |||||||||
Smoking | |||||||||||||||
Never | 8 | 33.3 | 16 | 66.7 | |||||||||||
Never | 10 | 43.5 | 13 | 56.5 | Former | 25 | 83.3 | 5 | 16.7 | ||||||
Former | 7 | 28.0 | 18 | 72.0 | |||||||||||
Former | 5 | 20.0 | 20 | 80.0 | Current | 17 | 53.1 | 15 | 46.9 | <0.001 ** | |||||
Current | 5 | 17.9 | 23 | 82.1 | 0.4 | ||||||||||
Current | 15 | 53.6 | 13 | 46.4 | Heavy alcohol use | 16/17.8 | |||||||||
0.04 * | Heavy alcohol use | ||||||||||||||
Heavy alcohol use | 14/18.4 | Never | 36 | 83.7 | 7 | 16.3 | |||||||||
14/18.2 | |||||||||||||||
Never | 14 | 35.9 | 25 | 64.1 | |||||||||||
Never | 17 | 44.7 | 21 | 55.3 | Former | 6 | 60.0 | 4 | 40.0 | ||||||
Former | 1 | 16.7 | 5 | 83.3 | |||||||||||
Former | 1 | 16.7 | 5 | 83.3 | Current | 13 | 61.9 | 8 | 38.1 | 0.09 | |||||
Current | 4 | 22.2 | 14 | 77.8 | 0.4 | ||||||||||
Current | 9 | 50.0 | 9 | 50.0 | 0.4 | T class | |||||||||
T Class | |||||||||||||||
T1-T2 | 46 | 51.1 | 12 | 13.3 | |||||||||||
T3-T4 | 23 | ||||||||||||||
T class | 25.6 | 9 | |||||||||||||
T1–T2 | 11 | 22.4 | 38 | 77.6 | 10.0 | 0.4 | |||||||||
T3–T4 | 9 | 32.1 | 19 | 67.9 | 0.4 | N class | |||||||||
N class | N0–N1 | 59 | 79.7 | 15 | 20.3 | ||||||||||
T1–T2 | 14 | 28.6 | 35 | 71.4 | |||||||||||
T3–T4 | 16 | 59.3 | 11 | 40.7 | 0.009 * | ||||||||||
N Class | N0–N1 | 12 | 19.0 | 51 | 81.0 | ||||||||||
N0–N1 | 23 | 36.5 | 40 | 63.5 | N2–N3 | 10 | 62.5 | 6 | 637.4 | 0.2 | |||||
N2–N3 | 8 | 42.9 | 0.006 * | ||||||||||||
N2–N3 | 57.1 | 7 | 53.8 | 6 | 46.2 | 0.2 | Stage | ||||||||
Stage | |||||||||||||||
Stage | I-II | 52 | 82.5 | 11 | 17.5 | ||||||||||
I–II | 9 | 17.0 | 44 | 83.0 | |||||||||||
I–II | |||||||||||||||
16 | 30.2 | 37 | 69.8 | III-IV | 17 | 63.0 | 10 | 37.0 | 0.04 * | ||||||
III–IV | 11 | 45.8 | 13 | 54.1 | 0.007 * | ||||||||||
III–IV | 14 | 60.9 | 9 | 39.1 | 0.01 * | Grade | Grade | Grade | |||||||
I | |||||||||||||||
1 | I33.3 | 2 | 66.7 | 0 | 0.0 | 2 | 100.0 | ||||||||
II | 3 | ||||||||||||||
I | 1 | 50.0 | 1 | 50.0 | |||||||||||
II | 8 | 53.3 | 7 | 46.7 | |||||||||||
23.0 | 10 | 77.0 | |||||||||||||
II | 6 | 46.2 | 7 | 53.8 | III | 60 | 83.3 | 12 | 16.7 | 0.009 * | III | 17 | 27.4 | ||
45 | 72.6 | 0.7 | |||||||||||||
III | 23 | 37.7 | 38 | 62.3 | 0.8 | Localization | |||||||||
Localization | |||||||||||||||
Localization | Tonsil | 48 | 90.6 | 5 | 9.4 | Tonsil | |||||||||
10 | 21.7 | 36 | 78.3 | ||||||||||||
Tonsil | 15 | ||||||||||||||
32.6 | 31 | 67.4 | Base of tongue | 17 | 77.3 | 5 | 22.7 | ||||||||
Base of tongue | 6 | 35.3 | 11 | 64.7 | Soft palate | ||||||||||
Base of tongue | 6 | 37.5 | 10 | 62.5 | 3 | 30.0 | 7 | 70.0 | Soft palate | 3 | 33.3 | 6 | |||
Soft palate | 6 | 66.7 | |||||||||||||
66.7 | 3 | 33.3 | Posterior wall of oropharynx | 1 | 20.0 | 4 | 80.0 | ||||||||
Posterior wall of oropharynx | 0.7 | ||||||||||||||
3 | 60.0 | 2 | 40.0 | 0.2 | HPV | ||||||||||
HPV | |||||||||||||||
HPV− | 9 | 29.0 | |||||||||||||
HPV− | 22 | 71.0 | |||||||||||||
18 | 60.0 | 12 | 40.0 | HPV+ | 11 | 23.9 | |||||||||
HPV+ | 12 | 33.3 | 34 | 66.6 | 0.003 * |